{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:42:39Z","timestamp":1792802559783,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1124\/jpet.112.191957","type":"journal-article","created":{"date-parts":[[2012,3,24]],"date-time":"2012-03-24T07:35:15Z","timestamp":1332574515000},"page":"572-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents"],"prefix":"10.1016","volume":"341","author":[{"given":"C.C.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Wing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"Rigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.112.191957_bib1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1155\/2000\/245964","article-title":"Do NSAIDs prevent colorectal cancer?","volume":"14","author":"Arber","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"10.1124\/jpet.112.191957_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas","volume":"348","author":"Baron","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.112.191957_bib3","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1053\/j.gastro.2006.08.079","article-title":"A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas","volume":"131","author":"Baron","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.112.191957_bib4","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0006-2952(98)00046-X","article-title":"Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent","volume":"55","author":"Bauer","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.112.191957_bib5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2003.11.021","article-title":"Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages","volume":"40","author":"Bibby","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.112.191957_bib6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.112.191957_bib7","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-08-1931","article-title":"Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I\/II clinical trial","volume":"15","author":"Daud","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.112.191957_bib8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1078-0432.CCR-09-2878","article-title":"Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy","volume":"16","author":"Dong","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.112.191957_bib9","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":"Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects","volume":"87","author":"Dredge","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.112.191957_bib10","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1200\/JCO.2007.13.8081","article-title":"Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy\u2013Cancer and Leukemia Group B Trial 30203","volume":"26","author":"Edelman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.112.191957_bib11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(09)60243-9","article-title":"Aspirin, salicylates, and cancer","volume":"373","author":"Elwood","year":"2009","journal-title":"Lancet"},{"key":"10.1124\/jpet.112.191957_bib12","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"key":"10.1124\/jpet.112.191957_bib13","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1158\/1078-0432.CCR-07-4013","article-title":"The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib","volume":"14","author":"Fidler","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.112.191957_bib14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ejca.2004.01.009","article-title":"Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery","volume":"40","author":"Fiebig","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.112.191957_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/(SICI)1097-4644(2000)77:34+<97::AID-JCB16>3.0.CO;2-Z","article-title":"COX-2 and colon cancer: potential targets for chemoprevention","volume":"34","author":"Fournier","year":"2000","journal-title":"J Cell Biochem Suppl"},{"key":"10.1124\/jpet.112.191957_bib16","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"10.1124\/jpet.112.191957_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/asheducation-2005.1.445","article-title":"The cardiovascular pharmacology of COX-2 inhibition","volume":"2005","author":"Fries","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1124\/jpet.112.191957_bib18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1124\/jpet.104.076877","article-title":"Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity","volume":"312","author":"Gierse","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.191957_bib19","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1124\/jpet.112.191957_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(07)70146-8","article-title":"Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study","volume":"8","author":"Gridelli","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.112.191957_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1039\/C1MD00017A","article-title":"Molecular obesity, potency and other addictions in drug discovery","volume":"2","author":"Hann","year":"2011","journal-title":"MedChemComm"},{"key":"10.1124\/jpet.112.191957_bib22","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1124\/jpet.112.191957_bib23","first-page":"4756","article-title":"A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients","volume":"9","author":"Higuchi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.112.191957_bib24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1535-7163.MCT-10-0106","article-title":"Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines","volume":"9","author":"Holbeck","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.112.191957_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1124\/jpet.112.191957_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrclinonc.2011.34","article-title":"High drug attrition rates\u2013where are we going wrong?","volume":"8","author":"Hutchinson","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"10.1124\/jpet.112.191957_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/01635580802401317","article-title":"Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis","volume":"60","author":"Ignatenko","year":"2008","journal-title":"Nutr Cancer"},{"key":"10.1124\/jpet.112.191957_bib28","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","article-title":"Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials","volume":"84","author":"Johnson","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.112.191957_bib29","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.bcp.2005.05.004","article-title":"Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention","volume":"70","author":"Kashfi","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.112.191957_bib30","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.1021\/bi101540g","article-title":"The chemical basis of pharmacology","volume":"49","author":"Keiser","year":"2010","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.112.191957_bib31","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1200\/JCO.2004.10.127","article-title":"Thalidomid: current role in the treatment of non-plasma cell malignancies","volume":"22","author":"Kumar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.112.191957_bib32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(94)91253-X","article-title":"Sulindac in familial adenomatous polyposis","volume":"343","author":"Labayle","year":"1994","journal-title":"Lancet"},{"key":"10.1124\/jpet.112.191957_bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","article-title":"Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo","volume":"17","author":"Lentzsch","year":"2003","journal-title":"Leukemia"},{"key":"10.1124\/jpet.112.191957_bib34","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-04-2478","article-title":"Valproic acid alters chromatin structure by regulation of chromatin modulation proteins","volume":"65","author":"Marchion","year":"2005","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.112.191957_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","article-title":"Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial","volume":"1","author":"Meyskens","year":"2008","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1124\/jpet.112.191957_bib36","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2010.29.6244","article-title":"Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial","volume":"28","author":"Midgley","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.112.191957_bib37","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"M\u00fcnster","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.112.191957_bib38","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study","volume":"25","author":"M\u00fcnster","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.112.191957_bib39","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.2009.25.4524","article-title":"Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Ning","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.112.191957_bib40","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.2006.09.2791","article-title":"Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer","volume":"25","author":"O'Byrne","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.112.191957_bib41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jnci\/81.14.1088","article-title":"Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm","volume":"81","author":"Paull","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/jpet.112.191957_bib42","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3181\/00379727-146-38268","article-title":"Liposome-encapsulated actinomycin D: potential in cancer chemotherapy","volume":"146","author":"Rahman","year":"1974","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1124\/jpet.112.191957_bib43","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer","volume":"348","author":"Sandler","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.112.191957_bib44","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1158\/0008-5472.CAN-05-3627","article-title":"Contributions of human tumor xenografts to anticancer drug development","volume":"66","author":"Sausville","year":"2006","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.112.191957_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.bcp.2008.04.017","article-title":"The anti-proliferative potency of celecoxib is not a class effect of coxibs","volume":"76","author":"Schiffmann","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.112.191957_bib46","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cell.2009.08.017","article-title":"Heterogeneity in cancer: cancer stem cells versus clonal evolution","volume":"138","author":"Shackleton","year":"2009","journal-title":"Cell"},{"key":"10.1124\/jpet.112.191957_bib47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrd2110","article-title":"The mighty mouse: genetically engineered mouse models in cancer drug development","volume":"5","author":"Sharpless","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.112.191957_bib48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.112.191957_bib49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/jpet.112.191957_bib50","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.112.191957_bib51","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.971.11.3","article-title":"50 years of preclinical anticancer drug screening: empirical to target-driven approaches","volume":"11","author":"Suggitt","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.112.191957_bib52","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1535-7163.MCT-06-0391","article-title":"Tumor models for efficacy determination","volume":"5","author":"Teicher","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.112.191957_bib53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1359-6446(04)03307-0","article-title":"Thalidomide as a novel therapeutic agent: new uses for an old product","volume":"10","author":"Teo","year":"2005","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.112.191957_bib54","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis","volume":"96","author":"Warner","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.112.191957_bib55","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2002-03-0939","article-title":"Antimyeloma efficacy of thalidomide in the SCID-hu model","volume":"100","author":"Yaccoby","year":"2002","journal-title":"Blood"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524182043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524182043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.112.191957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:45:45Z","timestamp":1739983545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524182043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0022356524182043"],"URL":"https:\/\/doi.org\/10.1124\/jpet.112.191957","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.112.191957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}